Amneal Pharmaceuticals, Inc. (AMRX) Stock Forecast
AMRX analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.57 / 5 from 7 analysts
- Price target
- $22.71 average of analyst targets
- Upside to target
- +18.4% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $0.21
- 52-week range
- $10.00 – $20.50
AMRX analyst ratings
7 analystsNumber of analysts at each rating.
AMRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AMRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.23 | $0.20 | $0.28 | $0.17 | +36.8% | 7 |
| Current fiscal year (2026) | $1.02 | $0.98 | $1.05 | $0.83 | +23.4% | 7 |
| Next fiscal year (2027) | $1.19 | $1.00 | $1.31 | $1.02 | +16.4% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AMRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $812.1M | $791.8M | $830.0M | +3.5% | 6 |
| Current fiscal year (2026) | $3.16B | $3.11B | $3.18B | +4.5% | 6 |
| Next fiscal year (2027) | $3.44B | $3.35B | $3.49B | +9.1% | 6 |
AMRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AMRX revenue: reported and forecast
AMRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.25 | $0.24 | $0.22 | $0.23 | $0.23 | −6.4% | 0 up · 1 down |
| Current fiscal year (2026) | $0.99 | $1.01 | $1.01 | $1.02 | $1.02 | +3.7% | 1 up · 0 down |
| Next fiscal year (2027) | $1.12 | $1.18 | $1.16 | $1.19 | $1.19 | +6.2% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AMRX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AMRX beat in 11 of 12.
What analysts expect from AMRX
7 analysts cover Amneal Pharmaceuticals; their consensus rating is strong buy (4.57 on a 1–5 scale, where 5 is a strong buy). The average price target is $22.71, 18.4% above the latest close of $19.18. Analysts expect earnings of $1.02 per share for 2026, +23.4% from a year earlier. For 2027 the average estimate is $1.19 per share on revenue of $3.4 billion. Amneal Pharmaceuticals beat the EPS estimate in 11 of the last 12 quarters.
Related: AMRX income statement, AMRX key metrics, AMRX chart. See the AMRX stock overview for the latest quote and news.
AMRX forecast FAQ
What is Amneal Pharmaceuticals's price target?
The average analyst price target for Amneal Pharmaceuticals is $22.71, 18.4% above the latest close of $19.18.
Is Amneal Pharmaceuticals a buy, hold or sell?
Of 7 analysts covering Amneal Pharmaceuticals, 4 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Amneal Pharmaceuticals's EPS forecast?
Analysts forecast $1.02 per share for 2026 (range $0.98 to $1.05); for 2027 the estimate is $1.19.
What is Amneal Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $3.2 billion, growth of 4.5%; for 2027 it is $3.4 billion.
When does Amneal Pharmaceuticals report earnings?
Amneal Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens; the EPS estimate is $0.21.
Does Amneal Pharmaceuticals usually beat earnings estimates?
Amneal Pharmaceuticals reported EPS at or above the analyst estimate in 11 of the last 12 quarters.